Previous 10 | Next 10 |
AIkido Pharma Announces Strategic Investment in MasterClass PR Newswire Masterclass Provides Members Access to Pre-Recorded Lectures by Top Experts NEW YORK , April 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Compan...
Cedars-Sinai Medical Center and AIkido Pharma Inc. to Codevelop Novel Immuno-Oncology Cancer Treatment PR Newswire NEW YORK , March 11, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company and Cedars-...
Cedars-Sinai Medical Center and AIkido Pharma Inc. Enter Into Master Collaboration Agreement PR Newswire NEW YORK , March 8, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has entered into a Mas...
AIkido Pharma (AIKI +1.4%) announced the issuance of an additional U.S. patent covering its pancreatic cancer drug DHA-dFdC, licensed from the University of Texas at Austin. The company said the U.S. Patent Office issued a U.S. Patent No. 11,219,633, which is expected...
AIkido Pharma Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug PR Newswire NEW YORK , March 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported an improvement in the m...
AIkido Pharma Inc. Announces Closing of $22 Million Registered Direct Offering PR Newswire NEW YORK , March 2, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced the closing of its previously announced registe...
AIkido Pharma (NASDAQ:AIKI) entered into a securities purchase agreement with certain institutional investors for purchasing 11K shares of Series O redeemable convertible preferred stock and 11K shares of Series P redeemable convertible preferred stock. Each share of Series O and Series ...
AIkido Pharma Inc. Announces $22 Million Registered Direct Offering PR Newswire NEW YORK , Feb. 25, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced that it has entered into a securities purchase agr...
AIkido Pharma is advancing anticancer and antiviral therapies backed by strong IP. The Company also invests in non-core businesses that contribute near-term monetization. The Company is flush with cash and has offered to buy back $3 million of shares. For further details see...
AIkido Pharma Announces Share Repurchase Program PR Newswire NEW YORK , Jan. 24, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI ) ("AIkido" or the "Company"), a clinical and early-stage drug development company, today announced that its board of di...
News, Short Squeeze, Breakout and More Instantly...
AIkido Pharma Inc. Company Name:
AIKI Stock Symbol:
NASDAQ Market:
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH) PR Newswire NEW YORK , Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) (the "Company") today announced that it has changed its name from AI...
AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes PR Newswire Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK , Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) (...
AIkido Share Repurchase Continues PR Newswire NEW YORK , Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authori...